Gut Bacteria Decide Whether Nutrients Feed Tumors or Fuel Immunity

A new discovery in the gut microbiota could fundamentally reshape how oncologists approach cancer therapy. Researchers at Weill Cornell Medicine have demonstrated that common intestinal bacteria are not passive residents of the digestive tract; they actively regulate whether dietary nutrients promote tumor growth or enhance the immune system’s capacity to fight cancer. 
Published in Cell Microbe and Host, the findings point to a potential new treatment and monitoring strategy. Rather than focusing exclusively on direct tumor targeting, future approaches may involve modulating the gut microbiome or tailoring diet to improve antitumor immune responses.  The study centers on Bacteroides ovatus, one of the most abundant bacteria in the human gut, and a gene it carries called bo-ansB. This gene encodes an enzyme that breaks down asparagine, an amino acid essential for the function of both cancer cells and immune cells.

''Our study suggests that we need to think about how the interplay of diet, gut microbiota and tumor-infiltrating immune cells could affect cancer growth and response to therapy. We can't overlook this key level regulation,'' said Dr. Chunjun Guo, associate professor of immunology at Weill Cornell Medicine.

The Asparagine Paradox

Inside tumors, nutrients are scarce. Cancer cells and CD8+ T cells—the immune system's assassins that directly attack tumors—compete for the same limited resources. Asparagine is particularly crucial: it supports protein synthesis and cell survival for both populations.

Using mouse models with human gut microbiota, the researchers discovered that the bo-ansB gene acts as a molecular switch. When gut bacteria carry this gene, they consume asparagine in the intestine before it enters the bloodstream. Less reaches the tumor, and CD8+ T cells become malnourished and ineffective; tumors thrive.

But when the researchers knocked out bo-ansB, bacteria could no longer deplete intestinal asparagine. The same asparagine-rich diet now favored immune cells over cancer cells. More asparagine reached the tumor microenvironment, and CD8+ T cells responded by transforming into a "stem-like" state—a renewable population that generates sustained waves of tumor-killing cells.

A Nutrient Gateway for Immune Cells

The mechanism hinges on a protein transporter called SLC1A5. When asparagine levels rise in tumors—which happens when bacteria lack bo-ansB—CD8+ T cells ramp up SLC1A5 production on their surface. This transporter imports asparagine, triggering the stem-like state associated with effective, long-lasting anti-tumor responses.

When researchers blocked SLC1A5, the benefits vanished. The transporter, they confirmed, is essential for asparagine to power immune cell transformation.

Perhaps most clinically relevant: mice fed asparagine-rich diets and colonized with bacteria lacking bo-ansB showed significantly enhanced responses to anti-PD-1 checkpoint inhibitor therapy—a cornerstone of modern cancer immunotherapy. The gut bacteria's metabolic activity directly influenced how well immunotherapy worked.

Rethinking Cancer Biology

The discovery upends conventional thinking about cancer nutrition. The traditional view focuses on starving tumors by restricting specific nutrients. This research reveals the opposite can be true: providing more of certain nutrients may actually help, if the gut microbiome is configured to deliver them preferentially to immune cells rather than tumors.

It's a three-way interaction that previous cancer research often missed. Diet, microbiome composition, and immune function aren't independent variables—they're inextricably linked, with gut bacteria serving as gatekeepers that control nutrient flow to distant battlefields where tumors and immune cells fight.

The team used sophisticated techniques to prove causation: germ-free mice, single-cell RNA sequencing, isotope tracing, and CRISPR gene editing. They showed that the bacterial enzyme works locally in the gut, controlling nutrient absorption rather than directly affecting tumors or immune cells. The specificity to a single gene—bo-ansB—rules out broader microbiome composition effects.

Toward Personalized Microbiome Medicine

The implications are profound. If bacterial genes determine treatment outcomes, then microbiome profiling could predict which patients will respond to immunotherapy. Dietary interventions could be tailored to individual microbiomes. Engineered probiotics might be designed to optimize nutrient delivery for cancer patients.

“We think it’s critical to continue studying interactions between diet, the microbiota and the immune system because different diets may enhance the immune system of one individual but not another, depending on the type of microbiota they have,” said Dr. Nicholas Collins, assistant professor of immunology and a member of the Friedman Center for Nutrition, both at Weill Cornell. “Our goal is personalized therapy, where we can tailor a specific diet that will synergize with the microbiota of an individual to boost the immune system against cancer.”

Translating these findings to patients won't be simple. The human gut microbiome is vastly more complex than that in laboratory mice, with hundreds of bacterial species and overlapping metabolic capabilities. Controlling diet in human populations is notoriously difficult. And there are safety questions: could boosting anti-tumor immunity trigger unwanted autoimmune responses?

Still, the research offers a fundamentally new framework for cancer treatment. Rather than targeting tumors directly, clinicians may reshape the gut microbiome or adjust diets to starve tumors while supercharging immune cells. It's precision medicine that integrates oncology, microbiology, immunology, and nutrition in ways previous models never anticipated.